Trial: 201806197

ADVL1521 – A Phase 2 Study of the MEK Inhibitor Trametinib (IND# 119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Phase

II

Principal Investigator

Hayashi, Robert

Disease Site

Myeloid and Monocytic Leukemia

Learn more about this study at: clinicaltrials.gov